The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors-Reference-Cited by-同舟云学术

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors

Published:2021-07 Issue: Volume: Page:
ISSN:2451-9456
Container-title:Cell Chemical Biology
language:en
Short-container-title:Cell Chemical Biology

Author:

Palve Vinayak^ORCID,Knezevic Claire E.,Bejan Daniel S.^ORCID,Luo Yunting,Li Xueli,Novakova Silvia,Welsh Eric A.,Fang Bin,Kinose Fumi,Haura Eric B.,Monteiro Alvaro N.^ORCID,Koomen John M.^ORCID,Cohen Michael S.,Lawrence Harshani R.,Rix Uwe

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry

Reference54 articles.

1. In vivo vizualisation of mono-ADP-ribosylation by dPARP16 upon amino-acid starvation;Aguilera-Gomez;Elife,2016

2. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors;Antolin;Oncotarget,2014

3. Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone;Aoyagi-Scharber;Acta Crystallogr. F Struct. Biol. Commun.,2014

4. The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation;Bolin;Cell. Mol. Life Sci.,2012

5. Regulation of mitochondrial poly(ADP-Ribose) polymerase activation by the beta-adrenoceptor/cAMP/protein kinase A axis during oxidative stress;Brunyanszki;Mol. Pharmacol.,2014

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities;Experimental Hematology & Oncology;2024-08-05

2. GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer;Cell Reports;2024-08

3. Exploring affinity chromatography in proteomics: A comprehensive review;Analytica Chimica Acta;2024-06

4. Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy;Cancers;2024-04-25

5. Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma;Molecular Cancer Therapeutics;2024-04-24